SCHEMBL6038953

SCHEMBL6038953

COc1cccc(-c2cnc(NS(=O)(=O)c3ccc(C)cc3)c(OCc3ccc(OC)c(OC)c3)n2)c1

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CCR4 P51679 1/20 0.59
MAPT P10636 5/20 0.43
LMNA P02545 3/20 0.42
ALDH1A1 P00352 2/20 0.42
MEN1 O00255 2/20 0.40
HPGD P15428 2/20 0.40
KMT2A Q03164 2/20 0.40
TSHR P16473 1/20 0.40
HTT P42858 1/20 0.40
KDM4E B2RXH2 1/20 0.40
CSF1R P07333 1/20 0.40
DYRK1A Q13627 1/20 0.40
CLK4 Q9HAZ1 1/20 0.40
KDM1A O60341 1/20 0.40
MAOA P21397 1/20 0.40
KMO O15229 1/20 0.39
FLT1 P17948 1/20 0.39
FLT4 P35916 1/20 0.39
KDR P35968 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6038560 0.91 CCR4 (0.58) CCR4MAPTALDH1A1MEN1KMT2A
SCHEMBL6038535 0.90 CCR4 (0.65) CCR4MAPTLMNAMEN1KMT2A
SCHEMBL6038467 0.89 CCR4 (0.56) CCR4MAPTALDH1A1MEN1KMT2A
SCHEMBL6038583 0.89 CCR4 (0.60) CCR4ALDH1A1MEN1KMT2ATSHR
SCHEMBL6038792 0.86 CCR4 (0.47) CCR4MAPTLMNAALDH1A1MEN1
SCHEMBL6038637 0.84 CCR4 (0.68) CCR4LMNAMEN1KMT2ATSHR
SCHEMBL6039115 0.83 CCR4 (0.53) CCR4
SCHEMBL6038499 0.82 CCR4 (0.82) CCR4
SCHEMBL6038778 0.79 CCR4 (0.65) CCR4LMNA
SCHEMBL6038722 0.79 CCR4 (0.47) CCR4MAPTLMNAALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060004010-A1 Ccr4 antagonist and medical use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2006-01-05 US disclosed
EP-1541563-A1 CCR4 ANTAGONIST AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004010-A1 Ccr4 antagonist and medical use thereof CCR4, CCR1, CCR9 CCR4 1/4885MAPT 3473/4885LMNA 4821/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.